UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine, 2018-11, Vol.62 (2), p.371-380

2018

Volltextzugriff (PDF)

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects

Clinical therapeutics, 2017-11, Vol.39 (11), p.2243-2259.e5

2017

Volltextzugriff (PDF)

Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes

The AAPS journal, 2020-01, Vol.22 (2), p.23, Article 23

2020

Volltextzugriff (PDF)

A Mechanism‐Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development

Journal of clinical pharmacology, 2017-07, Vol.57 (7), p.855-864

2017

Volltextzugriff (PDF)

Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer

Molecular Therapy: Oncology, 2024-09, Vol.32 (3), p.200864, Article 200864

2024

Volltextzugriff (PDF)

EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2ΔA MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E1387-E1387

2013

Volltextzugriff (PDF)

Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes

JCI insight, 2019-12, Vol.4 (24)

2019

Volltextzugriff (PDF)

Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort

Journal of the Endocrine Society, 2020-01, Vol.4 (1), p.bvz015

2020

Volltextzugriff (PDF)

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

Cardiovascular therapeutics, 2018-02, Vol.36 (1), p.n/a

2018

Volltextzugriff (PDF)

The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

Cardiovascular therapeutics, 2018-02, Vol.36 (1), p.n/a

2018

Volltextzugriff (PDF)

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5094-TPS5094

2021

Volltextzugriff (PDF)

A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development: Journal of Clinical Pharmacology

Journal of clinical pharmacology, 2017-07, Vol.57 (7), p.855-864

2017

Volltextzugriff (PDF)

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2574-2574

2018

Volltextzugriff (PDF)

Abstract # P-6: Robust Glucose and HbA1c Lowering After a Single Dose of Rn909 (Pf-06293620) in Type 2 Diabetes (T2D) SUBJECTS

Endocrine practice, 2016-12, Vol.22, p.16

2016

Volltextzugriff (PDF)

ROBUST GLUCOSE AND HBA1C LOWERING AFTER A SINGLE DOSE OF RN909 (PF-06293620) IN TYPE 2 DIABETES (T2D) SUBJECTS

Endocrine practice, 2016-12, Vol.22, p.16

2016

Volltextzugriff (PDF)

Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier

Pharmaceutical research, 2004-10, Vol.21 (10), p.1880-1885

2004

Volltextzugriff (PDF)

Pharmacokinetics of the newer benzodiazepines

Clinical pharmacokinetics, 1989-06, Vol.16 (6), p.337-364

1989

Volltextzugriff (PDF)

EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E1387

2013

Volltextzugriff (PDF)

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

Clinical cancer research, 1997-03, Vol.3 (3), p.409-417

1997

Volltextzugriff (PDF)

Effects of 12ￂ weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin

Cardiovascular therapeutics, 2018-02, Vol.36 (1)

2018

Volltextzugriff (PDF)

The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2[Delta]a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

Cardiovascular therapeutics, 2018-02, Vol.36 (1)

2018

Volltextzugriff (PDF)

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3079-3079

2016

Volltextzugriff (PDF)

Chapter 33 - Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules

Atkinson's Principles of Clinical Pharmacology, 2022, p.611-651

Fourth Edition, 2022

Volltextzugriff (PDF)

Recombinant human factor IX : Replacement therapy, Prophylaxis, and pharmacokinetics in canine hemophilia B

Blood, 1996-10, Vol.88 (7), p.2603-2610

1996

Volltextzugriff (PDF)

Chapter 34 - Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules

Principles of Clinical Pharmacology, 2012, p.547-570

Garzone, Pamela D.

Third Edition, 2012

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(9)
Dose-Response Relationship, Drug
(5)
Low Density Lipoprotein
(5)
Monoclonal Antibodies
(5)
Pharmacology & Pharmacy
(5)
Adult
(4)
Biological And Medical Sciences
(4)
Bococizumab
(4)
Cholesterol
(4)
Female
(4)
Male
(4)
Middle Aged
(4)
Pharmacokinetics
(4)
Studies
(4)
Aged
(3)
Animals
(3)
Antibodies, Monoclonal, Humanized - Administration & Dosage
(3)
Antibodies, Monoclonal, Humanized - Pharmacokinetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects

Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes

A Mechanism‐Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development

Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer

EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2ΔA MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS

Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes

Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC)

A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development: Journal of Clinical Pharmacology

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors

Abstract # P-6: Robust Glucose and HbA1c Lowering After a Single Dose of Rn909 (Pf-06293620) in Type 2 Diabetes (T2D) SUBJECTS

ROBUST GLUCOSE AND HBA1C LOWERING AFTER A SINGLE DOSE OF RN909 (PF-06293620) IN TYPE 2 DIABETES (T2D) SUBJECTS

Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier

Pharmacokinetics of the newer benzodiazepines

EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

Effects of 12ￂ weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin

The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2[Delta]a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results

Chapter 33 - Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules

Recombinant human factor IX : Replacement therapy, Prophylaxis, and pharmacokinetics in canine hemophilia B

Chapter 34 - Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules

Suchergebnisse filtern